This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Bluebird (BLUE) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Bluebird (BLUE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
bluebird (BLUE): Strong Industry, Solid Earnings Estimate Revisions
by Zacks Equity Research
bluebird (BLUE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Bristol-Myers Gets Refusal to File Letter for CAR-T Therapy BLA
by Zacks Equity Research
Bristol-Myers' (BMY) BLA seeking approval for CAR-T therapy candidate, idecabtagene vicleucel, for treating relapsed and refractory multiple myeloma gets FDA's refusal. The company plans to re-submit the BLA by July.
Bluebird Bio (BLUE) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Bluebird (BLUE) delivered earnings and revenue surprises of 7.61% and 147.26%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Is a Surprise Coming for bluebird bio (BLUE) This Earnings Season?
by Zacks Equity Research
bluebird bio (BLUE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
What's in Store for Ensign Group's (ENSG) Earnings in Q1?
by Zacks Equity Research
Ensign Group's (ENSG) Q1 results are likely to reflect a better revenue stream.
bluebird bio (BLUE) Catches Eye: Stock Jumps 6%
by Zacks Equity Research
bluebird bio (BLUE) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Bristol Myers, bluebird Submit BLA for Myeloma Drug to FDA
by Zacks Equity Research
Bristol Myers (BMY) and bluebird file a biologics license application to the FDA seeking approval of idecabtagene vicleucel for heavily pre-treated patients with multiple myeloma. Stock gains.
Bluebird (BLUE) Down 47.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Bluebird (BLUE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Bluebird (BLUE) Down 47.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Bluebird (BLUE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
bluebird (BLUE) Q4 Earnings Miss Estimates, Revenues In Line
by Zacks Equity Research
bluebird (BLUE) reports a wider-than-expected loss and in-line revenues for the fourth quarter of 2019.
Bluebird Bio (BLUE) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Bluebird Bio (BLUE) closed at $91.77, marking a +1.75% move from the previous day.
Novo Nordisk's Shares Up in a Year on Pipeline Progress
by Zacks Equity Research
Novo Nordisk's (NVO) shares have gained in the past year as it makes significant progress in pipeline development.
bluebird (BLUE) Catches Eye: Stock Jumps 6.8%
by Zacks Equity Research
bluebird (BLUE) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Biotech Stock Roundup: ASH Data in Focus, Amgen Gets FDA Nod to Remicade Biosimilar
by Zacks Equity Research
The biotech sector witnesses pipeline updates from the annual ASH meet.
Fate (FATE) Announces Encouraging Data on Immunotherapies
by Zacks Equity Research
Fate (FATE) gains on positive data from cellular immunotherapies and preclinical study data.
bluebird Reports Positive Top-Line Data on Myeloma Drug
by Zacks Equity Research
bluebird (BLUE) and partner Bristol-Myers report positive top-line results from a phase II study on idecabtagene vicleucel in patients with relapsed and refractory multiple myeloma.
Are Options Traders Betting on a Big Move in bluebird (BLUE) Stock?
by Zacks Equity Research
Investors need to pay close attention to bluebird (BLUE) stock based on the movements in the options market lately.
Global Blood's (GBT) Oxbryta Secures FDA Approval for SCD
by Zacks Equity Research
Global Blood's (GBT) Oxbryta wins the FDA nod to address sickle cell disease in patients aged 12 years and above. The approval comes three months ahead of schedule.
Novartis Receives FDA Nod for Adakveo in Sickle Cell Disease
by Zacks Equity Research
Novartis (NVS) gets FDA nod for Adakveo to reduce the frequency of pain crises in adult and pediatric SCD patients.
Bluebird Bio (BLUE) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Bluebird (BLUE) delivered earnings and revenue surprises of -5.67% and -15.94%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Bluebird Bio (BLUE) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Bluebird (BLUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Jazz Starts CAR T-cell Linked Neurotoxicity Study Enrollment
by Zacks Equity Research
Jazz (JAZZ) enrolls first patient in a mid-stage study to evaluate defibrotide in prevention of neurotoxicity in relapsed/refractory DLBCL patients receiving CAR T-cell therapy.
bluebird Inks Genome Editing Research Deal With Novo Nordisk
by Zacks Equity Research
bluebird (BLUE) signs a collaboration contract with Novo Nordisk to develop next-generation in vivo genome editing therapies for the treatment of genetic disorders including hemophilia.
FDA Grants Priority Review to Global Blood's SCD Candidate
by Zacks Equity Research
The FDA accepts Global Blood's (GBT) new drug application for voxelotor under priority review to treat sickle cell disease. A decision is expected on Feb 26, 2020.